Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.54 |
| ▸ | IMPDH2 | P12268 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | CLK1 | P49759 | 1/20 | 0.50 |
| ▸ | GSK3B | P49841 | 1/20 | 0.50 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.50 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.50 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.50 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.49 |
| ▸ | HTR2B | P41595 | 1/20 | 0.49 |
| ▸ | HTR5A | P47898 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26259955 | 0.82 | NISCH (0.61) | HSD17B10MAPK1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL5230929 | 0.82 | PRKCB (0.72) | GSK3BPIM1PRKD3CCNB2CCNE2 | |
| SCHEMBL2406362 | 0.77 | DYRK1A (0.56) | IMPDH2GSK3BDYRK1AMAP3K14ALDH1A1 | |
| SCHEMBL26259965 | 0.77 | NISCH (0.54) | ALDH1A1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL9287236 | 0.76 | NISCH (0.64) | ALDH1A1SMN1; SMN2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL1202543 | 0.76 | IMPDH2 (0.63) | HSD17B10IMPDH2MAPK1HTR2CALDH1A1 | |
| SCHEMBL28228155 | 0.76 | HSD17B10 (0.59) | HSD17B10IMPDH2MAPK1CLK1GSK3B | |
| SCHEMBL7287655 | 0.75 | MAPT (0.60) | HTR2CHTR2BALDH1A1MAPTLMNA | |
| SCHEMBL14886257 | 0.74 | NISCH (0.61) | ALDH1A1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL8033955 | 0.74 | MEN1 (0.63) | HSD17B10MAPK1ALDH1A1MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117024759-A | Organic Pt metal macrocyclic group two-dimensional supermolecule assembly constructed based on oriented cation-pi action, and preparation method and application thereof | 陕西中医药大学 | 2023-11-10 | — | — | CN | claimed |
| CN-106916144-B | N-alkyl substituted indole-imidazole salt compound and preparation method thereof | 云南民族大学 | 2020-05-05 | — | — | CN | claimed |
| CN-106916144-A | N alkyl substitution indoles-imidazole salt compound and preparation method thereof | 云南民族大学 | 2017-07-04 | — | — | CN | claimed |
| CN-103145710-B | The synthetic method of indole-imidazole compound | BEIJING UNIVERSITY OF TECHNOLOGY (CN) | 2015-08-19 | — | — | CN | claimed |
| US-20040006126-A1 | Etoposide analogs and methods of use thereof | NIH-DEITR | 2004-01-08 | — | — | US | claimed |
| WO-2004000859-A2 | ETOPOSIDE ANALOGS AND METHODS OF USE THEREOF | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2003-12-31 | — | — | WO | claimed |
| US-6566393-B1 | For therapy of cancer | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2003-05-20 | — | — | US | claimed |
| JP-11199583-A | — | — | None | — | — | JP | disclosed |
| JP-11199582-A | — | — | None | — | — | JP | disclosed |
| JP-2188579-A | — | — | None | — | — | JP | disclosed |
| WO-2024006252-A1 | DUAL INHIBITION OF MDM2 AND EIF2-ALPHA INDUCES CELL DEATH IN MULTIPLE CANCER CELL TYPES | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2024-01-04 | — | — | WO | disclosed |
| CN-117024759-A | Organic Pt metal macrocyclic group two-dimensional supermolecule assembly constructed based on oriented cation-pi action, and preparation method and application thereof | 陕西中医药大学 | 2023-11-10 | — | — | CN | disclosed |
| CN-117024759-A | Organic Pt metal macrocyclic group two-dimensional supermolecule assembly constructed based on oriented cation-pi action, and preparation method and application thereof | 陕西中医药大学 | 2023-11-10 | — | — | CN | disclosed |
| CN-101679382-A | 3-imidazolyl-indoles for the treatment of proliferative diseases | NOVARTIS AG | 2010-03-24 | — | — | CN | disclosed |
| EP-2142535-A2 | 3-IMIDAZOLYL-INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Novartis Ag (CH) | 2010-01-13 | — | — | EP | disclosed |
| WO-2009011836-A1 | BETA CARBOLINE DERIVATIVES AS ANTIDIABETIC COMPOUNDS | MERCK & CO., INC. (US) | 2009-01-22 | — | — | WO | disclosed |
| WO-2008119741-A2 | 3-IMIDAZOLYL-INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2008-10-09 | — | — | WO | disclosed |
| JP-H11199582-A | 4(5)-(3-INDOLYL) IMIDAZOLE DERIVATIVE | SAGAMI CHEM RES CENTER | 1999-07-27 | — | — | JP | disclosed |
| JP-H11199583-A | 4(5)-(3-INDOLYL) IMIDAZOLE DERIVATIVE | SAGAMI CHEM RES CENTER | 1999-07-27 | — | — | JP | disclosed |
| JP-H02188579-A | INDOLYLIMIDAZOLE DERIVATIVE | TAISHO PHARMACEUT CO LTD | 1990-07-24 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006126-A1 | Etoposide analogs and methods of use thereof | LPXN, TET2, TH | HSD17B10 2666/4885IMPDH2 1553/4885MAPK1 4462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.